Objective: This study aimed to determine the associations between guideline-concordant pharmacotherapy for depression and the use of health services in the year following diagnosis.
M ajor depressive disorder affects up to 4.6% of Canadians annually, [1] [2] [3] [4] is currently ranked as the fourth leading cause of disability worldwide, 5 and is associated with increased risks for psychosocial disability, 2,6 lost work productivity, 2,7-10 mortality, 11 suicide, 10, [12] [13] [14] and increased use of mental health and medical services. 15 Effective antidepressant treatment results in symptom remission, 16 improved interpersonal and occupational functioning, 7 reduced risks for suicide 14 and disability from concurrent medical conditions, and a reduction in health care use. 4, 17 Although antidepressant use is increasing, [18] [19] [20] for most depression patients, pharmacotherapy is lacking or suboptimal. [21] [22] [23] [24] [25] [26] [27] [28] [29] Many patients do not receive antidepressants, 21, 22 and in one study of patients from 4 large primary care clinics in one health maintenance organization, up to 40% of patients discontinued their antidepressants within 6 weeks of beginning treatment. 26 Mental health practitioners and psychiatrists are more likely than primary care physicians to prescribe antidepressants 21, 23, 28 and to do so in appropriate dosages, 28 but inappropriate antidepressant prescription is found in all specialties. 22 Failure to prescribe appropriately early in the depressive episode may contribute to the development of chronic depression because medications other than antidepressants are not effective at reducing depressive symptoms and because inadequate dosing results in treatment nonresponse, which may in turn increase the risks for premature discontinuation and relapse. 30, 31 To improve the treatment of depressive disorders, CANMAT released guidelines in 1999 to assist physicians with prescribing decisions related to depression in primary care. 32 More detailed than US guidelines published at the time, 33 the CANMAT recommendations specified first-, second-and third-line antidepressants to be prescribed for unipolar depression. The guidelines were distributed by pharmaceutical company representatives. However, distribution alone does not guarantee change in clinical practice. 34 To date, little is known about both the extent to which the pharmacotherapy delivered in response to a newly diagnosed episode of depression conforms to guidelines and how receiving recommended pharmaocotherapy affects health services use following diagnosis. Thus this study aimed to determine how receiving recommended pharmacotherapy for a newly diagnosed episode of depression was associated with subsequent use of ambulatory and inpatient services during the year following diagnosis. We hypothesized that guideline concordance would be associated with more visits to prescribing physicians, fewer visits to other physicians and emergency departments, and decreased odds of hospitalization.
Methods

Data Source
This population-based, retrospective cohort study used 3 databases of the Quebec Health Insurance Plan, RAMQ. RAMQ pays for medical services for all residents and drug services for individuals receiving social assistance, lacking private or group insurance, or aged 65 years and older (not relevant to this study). All pharmacy and medical services claims data are contained within the RAMQ databases and encrypted to maintain patient and physician anonymity.
Selection of Subjects
We identified cases for a 6-month period, from October 1, 2000, to March 31, 2001 . We identified beneficiaries aged 18 to 64 years at study entry who had been diagnosed with a new episode of depression (no diagnosis in the 365 days prior to the study period) by either primary care physicians or psychiatrists and who were registered with the public drug plan between October 1, 1999, and March 31, 2002 . We then obtained all pharmaceutical records for this period. We created 2 observation intervals for each patient enrolled. The first was a 1-year follow-up period from the date of the first diagnostic coding of depression, during which eligible patients had to remain alive. The second was a 1-year antecedent period from the date of the first diagnostic coding of depression, during which all beneficiaries with a diagnosis of possible depression were excluded to retain only patients with newonset disorders.
Eligible patients filled a prescription for at least one psychoactive medication in the RAMQ (2003) medication list (Table  1) during the 31 days following the depression diagnosis. The index dispensing was the first identified psychoactive medication pharmacy claim within this 31-day interval. We excluded the following: patients who did not fill psychoactive medication prescriptions within the first 31 days following diagnosis; patients who had more than one antidepressant prescription claim at the index dispensation (because different recommendations pertain to this population 32 ); patients who had a change in psychiatric diagnosis before the index dispensation (that is, from depression to something else); (this was to exclude medications prescribed for the latter diagnosis); patients who had used an antidepressant during the previous 365 days; patients who received treatment outside the province of Quebec (medication data would not be in the RAMQ database); and patients diagnosed with thyroid disorders, epilepsy, all psychotic disorders (including bipolar disorders), and pregnancy during the year preceding or following the index date. These exclusions permitted the assessment of guideline-concordant pharmacotherapy for typical depression (mild-to-moderate), anxious depression, melancholic depression, and dysthymia.
Definition of Depression
Diagnosis was based on the first diagnostic coding of depressive disorder during the 6-month case identification period. We obtained the data from the RAMQ medical services database. Patients received one diagnosis per physician visit whether or not medication was prescribed. Although RAMQ uses the ICD-9 35 diagnostic codes, some physicians may have used the DSM-IV 36 codes, which are more detailed for mental disorders. To compensate for this discrepancy, we created an algorithm to retain patients with probable depression. Our physician experts identified 19 diagnostic codes that might have been used to indicate depression (a list is available from the authors upon request). Of these, we selected the codes for which the corresponding diagnoses were common to both the ICD-9 and DSM-IV (that is, dysthymia and depression NOS).
Independent Variables
Patient characteristics included age, sex, and region of residence (urban, intermediate, rural, distant); type of insurance (either welfare recipients or adherents, that is, general population without private or group insurance, or both, for those who changed status during the study period); other mental disorders such as alcohol or pharmacologic dependence (yes or no) and personality disorder (yes or no); and medical comorbidity (yes or no). We assessed medical comorbidity with a chronic disease score developed and validated for use with pharmacy claims data. 37 The characteristics of the diagnosing and prescribing physician included specialty. The health system variables included the establishment of diagnosis (in hospital, emergency, or outpatient setting) and practice pattern (a binary variable indicating whether the patient's physician both diagnosed depression and prescribed treatment).
Measures of Guideline-Concordant Pharmacotherapy
We obtained the data for assessing guideline concordance from the RAMQ pharmacy claims database, which holds information on filled prescriptions. We measured 3 criteria: the dispensing of the recommended starting drug, the dosage, and the duration. We considered the recommended starting drug an index dispensing for a first-line medication listed by CANMAT; this medication should be prescribed in response to a new depression diagnosis. First-line medications were the antidepressants citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, bupropion, nefazodone, venlafaxine, moclobemide, and imipramine. Recommended starting dosage was defined as a daily dose of an antidepressant that was within the therapeutic range detailed in the CANMAT guidelines. 32 The daily dose was calculated as (dose´quantity) / duration of prescription. We defined the recommended treatment duration as the use of an antidepressant for at least 180 days following treatment initiation. We considered this criterion fulfilled when a minimum supply of 150 days' worth of medication (approximately 80%) was prescribed. When the first drug dispensed remained the same throughout treatment, we used the index dispensation date and the sum of the prescribed durations to calculate the total duration. When a switch, addition, or change in dosage occurred during the first 12 weeks of treatment, we assumed that no benefit was derived from the initially prescribed drug. We then defined a new index dispensing, and determined the starting dosage and duration for the newly dispensed drug. 38 Low-dose trazodone (< 150 mg daily) was not considered antidepressant treatment because it is used to aid sleep.
We assessed health services use during the 1 year following treatment initiation. We measured use of ambulatory health services by the total numbers of patient visits to the prescribing physician, to other physicians, and to the emergency department, which we considered mutually exclusive categories. Use of inpatient services was a binary variable representing hospitalization.
Statistical Analyses
We used the Statistical Analysis System (SAS) for Windows 8.02 to conduct analyses. 39 We used descriptive statistics to characterize the study sample, and we compared subjects by receipt of first-line medication status using t tests and chi-square tests, as appropriate. We employed a GEE approach, 40 using PROC GENMOD, 41 for measures of ambulatory health service use (Poisson distribution) and inpatient service use (binary distribution). GEE models account for clustered data (possible dependence of different patients of the same physician) as well as for the unbalanced structure of the data as the number of patients varied across physicians. GEE indicated 1643 distinct physician clusters that ranged in size (number of patients) from 1 to 11. To arrive at the final models, we screened indicators of guideline concordance for statistical significance (P < 0.05) in separate bivariate GEE analyses. We then entered all variables into one multivariable model to identify the independent determinants of health service use. We calculated the continuous and binary outcomes, rate ratios, and ORs, as well as the associated 95%CIs, by exponentiating the parameter estimates.
Receipt of the recommended starting dosage and duration of treatment were conditional on receiving an antidepressant. Thus the multivariate models for these indicators included one indicator of guideline concordance, patient age, sex, region of residence, type of insurance, medical comorbidity, other mental disorders, and having the same diagnosing and prescribing physician. We excluded the establishment of diagnosis from the multivariate models as it was highly related to the diagnosing physician's specialty (for example, 98% of patients diagnosed in outpatient clinics were diagnosed by primary care physicians). To reduce the number of measures of association reported but still identify additional variables associated with health service use, we generated 4 multivariate models that excluded all indicators of guideline concordance. We considered 2-tailed P values less than 0.05 statistically significant. We obtained approval from the Université de Montréal Faculty of Medicine Research Ethics Committee prior to beginning the study.
Results
Description of Cohort
Analysis of filled prescription claims indicated that 2742 eligible beneficiaries received psychoactive medication within 31 days of diagnosis of a newly diagnosed episode of depression. Mean age was 42.1 years, SD 12.2. Of patients, 1745 (64%) were women, 111 (4%) had other mental disorders, and 1164 (43%) had medical comorbidity ( Table 2 ). Most patients lived in central and outlying regions (32% and 37%, respectively) and had no private or group insurance (62%). Most patients were diagnosed in outpatient clinics (92%), diagnosed (97%) and treated in primary care (95%), and diagnosed and treated by the same physician (89%). The average number of visits to outpatient clinics and inpatient hospital days in the previous year did not differ by receipt of first-line medication status (Table 2) . Table 3 shows the number of patients whose treatment was in concordance with the CANMAT guidelines. Overall, only 208 (8%) patients were dispensed the recommended medication, dosage, and duration of treatment.
Guideline Concordance
Of beneficiaries to whom psychoactive medication was dispensed, 2047 (75%) received an antidepressant as the initial starting drug and 1958 (71%) received a recommended first-line antidepressant. Of patients who were dispensed antidepressants, 1297 (63%) received the recommended starting dosage and 304 (15%) received the recommended duration to the initial and second dispensings. We did not evaluate the third and fourth dispensings.
Health Service Use
In the year following diagnosis, patients made a median of 2 (IQR 1 to 3) visits to prescribing physicians, no visits (IQR 0 to 1) to other physicians, and no visits (IQR 0 to 0) to the emergency department. In total, 497 (18%) patients were hospitalized, 245 (49%) of whom had only one hospitalization; 431 (15.7%) were hospitalized in the year prior to diagnosis, of whom 148 (29.8%) were also hospitalized in the year following diagnosis. Predictors of health service use are presented in Table 4 .
Prescribing Physician Visits
In both univariate and multivariate models, recommended first-line medication (z = 8.88, df 1, P = 0.001 and z = 6.17, df 11, P = 0.001, respectively), starting dosage (z = 7.43, df 1, P = 0.001 and z = 5.70, df 11, P = 0.001, respectively), and duration (z = 10.42, P = 0.001 and z = 9.49, P = 0.001, respectively) were associated with more visits to prescribing physicians. Additional determinants of more visits to prescribing physicians included having the same diagnosing and prescribing physician (95%CI, 3.63 to 7.56, OR 5.24; z = 8.90, df 11, P = 0.001). Medical comorbidity (95%CI, 0.96 to 0.99, OR 0.98; z = -2.71, df 11, P = 0.007) and welfare recipient status (95%CI, 0.74 to 0.89,OR 0.81; z = -4.49, df 11, P = 0.001) were associated with fewer visits (data not shown).
Other Physician Visits
In univariate analysis, recommended first-line medication was associated with fewer visits to other physicians (z = -2.20, df 1, P = 0.028). (4) 69 (3) 48 (2) 64 (3) 43 (2) 24 (1) 47 (6) 26 (3) 24 ( (32) 1002 (37) 664 (24) 185 (7) 12 (0) 607 (31) 712 (36) 497 (25) 133 (7) 9 (1) 272 (35) 290 (37) 167 (21) 52 (7) 3 (0) (3) 42 (2) 2445 (89) 27 (1) 194 (7) 2521 (92) 1902 (97) 46 (2) 10 (1) 1836 (94) 12 (1) 108 (6) 1838 (94) 715 (91) 37 (5) 32 (4) 609 (78) 15 (2) 86 (11) 683 ( 3.25, OR 1.92; z = 2.45, df 11, P = 0.015) was associated with more visits to other physicians, while age (95%CI, 0.98 to 1.00, OR 0.99; z = -2.98, df 11, P = 0.003) and having the same diagnosing and prescribing physician (95%CI, 0.23 to 0.37, OR 0.28; z = -9.68, df 11, P = 0.001) were associated with fewer visits (data not shown). Having the same diagnosing and prescribing physician was associated with fewer visits (95%CI, 0.27 to 0.46,OR 0.36, z = -7.73, df 11, P = 0.001) (data not shown).
Emergency Department Visits
Hospitalization
In both univariate and multivariate analyses, receipt of recommended first-line medication (z = -4.18, df 1, P = 0.001 and z = -2.55, df 11, P = 0.011, respectively) was associated with reduced odds of hospitalization ( Using combinations of the three measures of guideline concordance, dose-response relations were found for prescribing physician and emergency department visits (first-line medication and duration) and for other physician visits (first-line medication, dose, and duration).
All of the above-mentioned multivariate analyses were repeated for health service use in the 6 months following diagnosis. There were few changes in the measures of association.
Discussion
This study evaluated the relation between the receipt of guideline concordant pharmacotherapy and health service use in the year following the diagnosis of new episodes of depression in a population of adults. We found independent associations between the receipt of recommended first-line medication, starting dose and duration, and more visits to the prescribing physician. These relations were anticipated because patient adherence to antidepressants warrants that physicians closely monitor the patient's progress in terms of depressive symptoms, medication side effects, and suicidal ideations. Among patients given pharmacotherapy, receipt of any antidepressant was associated with more visits to the emergency department, while receipt of a first-line antidepressant was associated with lower odds of hospitalization. Guideline concordant pharmacotherapy was not associated with visits to other physicians or to the emergency department, suggesting that such visits are independent of the receipt of appropriate medication. Corroborating results from the sensitivity analyses that evaluated 6-month use of services further strengthened these findings. The extent of the guideline concordance produced dose-response relations with services use, suggesting the importance of adherence to the CANMAT guidelines. As such, the side effects profile of first-line antidepressants may be more favourable than that of other antidepressants, which in turn increases patients' adherence to medication thereby allowing them to receive the full benefit of antidepressant therapy.
Relational continuity of care 42 (that is, the patient had the same diagnosing and prescribing physician) was consistently identified as a strong determinant of more visits to prescribing physicians, fewer visits to other physicians and the emergency department, and reduced the odds of hospitalization. Our findings mirror those of others 43 who demonstrated fewer emergency department visits and more preventive health care for patients with continuity of care. Given that 91% of primary care physicians were both the diagnosing and the prescribing physician, primary care physicians should be encouraged that their ongoing relationships may help to curb excess use of ambulatory and inpatient health services among depression patients.
As was found in other studies, 21,28 most patients who received psychoactive medication were undertreated. Although some patients possibly opted for psychotherapy, it is likely that many received inadequate pharmacologic treatment. For example, 25% of patients initially received psychoactive medication other than antidepressants, 83% of whom were prescribed a benzodiazepine. These findings corroborate those of Tylee and others 44 and Valenstein and colleagues, 45 who found that benzodiazepines are commonly used in the management of depressive disorders. Although concomitant therapy may reduce depressive symptoms, 46 suppress SSRI side effects, 47 improve adherence to treatment, 46 and reduce the risk of suicide by lowering anxiety, 47 benzodiazepines are associated with increased risks for sedative effect, dependence, and worsening of depression. 48 The finding, however, that over one-third of patients received benzodiazepines indicates that physicians are attempting to address a compelling clinical phenomenon. Further, whereas 48% of patients received a recommended first-line medication and starting dosage, only 11% also received medication for the recommended duration. Thus, despite using both health services and medication, many treated patients could have been at risk for relapse and chronic depression. 30 Population administrative database studies have limitations that should be considered on interpreting the findings. The validity of diagnoses cannot be established, although physicians tend to under diagnose depression. [49] [50] [51] [52] Provision of psychotherapy was not evaluated because psychologist services are not covered by RAMQ. Although pharmacy claims were proxies for patient consumption and physician prescribing, We generated models for starting dosage and duration only for patients who were dispensed antidepressants. We adjusted multivariate models for patient age and sex, medical comoribidity, other mental disorder, region of residence, type of insurance, and having the same diagnosing and prescribing physician. b P < 0.05 comparing claims data with patient self-report of antidepressant use is satisfactory (ê = 0.70). 53, 54 No information was available for case severity or for medication samples provided. Some physician visits for surgical procedures were missing because they are incorporated into the cost of the procedure. We did not evaluate the link between guideline concordance and suicide because our study included only patients who remained alive for the duration of the study. The use of an algorithm to retain probable depression did not permit calculation of standardized rates of treatment. Generalizability of our findings may be limited to uncomplicated depression because we excluded patients with other psychiatric diagnostic codes. Generalizability may also be limited to individuals of lower socioeconomic status because most patients registered in the drug plan are of lower socioeconomic status. Some individuals who had a previous illness and were not treated in the observational year might not have received a recommended first-line medication because of known ineffectiveness or intolerability. Given that we evaluated hospitalization in the year following treatment, the relation between the receipt of the recommended duration of treatment and hospitalization should be interpreted as correlational rather than prospective. Finally, if patients who did not fill their prescriptions differ systematically on the joint distributions of guideline concordant criteria and health services use from patients who did, our study would produce biased results. Study strengths include that we included only patients diagnosed with depression, because antidepressants are commonly prescribed for medical conditions not addressed by depression practice guidelines. 55 Moreover, the focus on the initial medications dispensed in response to a newly diagnosed episode of depression permitted us to assess guideline concordant pharmacotherapy for depression. Further research using a prospective study design is warranted to confirm our findings.
Most of depression patients received recommended first-line medication, but only a few also received the recommended starting dosage and duration. Guideline concordance was associated with more visits to the prescribing physician and lower odds of hospitalization in the year following diagnosis. Given that most depression was diagnosed and treated in We adjusted each model for patient age, sex, medical comorbidity, other mental disorder, region of residence, type of insurance, having the same diagnosing and prescribing physician, and the indicator of guideline-concordant pharmacotherapy. We generated models for starting dosage and duration only for patients who were dispensed antidepressants. b P < 0.05 primary care and that relational continuity was linked to fewer costly visits (emergency department and hospitalization), further attempts to support primary care physicians' management of depression are warranted. By documenting the pharmacologic treatment dispensed in response to a newly diagnosed episode of depression as well as its impact on health care service use, this study provides information to patients, clinicians, and decision makers that may be used to improve prescribing practices, patient follow-up, and delivery of appropriate pharmaceutical therapy. Our results may also help with the development of interventions aimed at improving depression treatment and reducing inappropriate use of health services. 
